Baird says Dendreon's (DNDN -8.5%) Provenge may have a difficult road to commercial acceptance...
Monday, June 4, 2012, 12:38 PM ETBaird says Dendreon's (DNDN -8.5%) Provenge may have a difficult road to commercial acceptance especially after this weekend's ASCO meeting in which both Bristol Myers (BMY flat) and Medivation (MDVN -2%) published impressive trial results for their prostate drugs. The firm loweres its 2014 and 2015 estimates for Provenge and said the drug may have trouble remaining relevant.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles